What kind of medicine is neratinib/neratinib and what are its indications?

Neratinib/Neratinib (Neratinib) is a new generation of targeted therapy drugs that are tyrosine kinase inhibitors. It is used to treatHER2 (human epidermal growth factor receptor 2)-positive breast cancer. HER2-positive breast cancer is a specific type of breast cancer that accounts for approximately 15-20% of breast cancer patients. Under normal circumstances, HER2 receptors regulate cell growth and spread through signaling. However, inHER2-positive breast cancer, mutations or overexpression of the HER2 gene lead to overactive signaling, promoting abnormal proliferation and invasion of cancer cells.

Neratinib is mainly suitable for patients with HER2-positive early breast cancer who have received first-line treatment in the past. First-line treatment usually includes surgery, radiation therapy, and chemotherapy. Neratinib may be used as an adjuvant treatment option to reduce the risk of cancer recurrence. In addition, neratinib is also used in the treatment of HER2-positive advanced breast cancer. For patients with metastatic or locally advanced breast cancer, neratinib can provide a more comprehensive treatment effect when combined with other drugs, such as chemotherapy drugs or endocrine therapy drugs.

The mechanism of action of neratinib is to inhibit the growth of cancer cells by inhibiting the activation ofHER2 receptor and other related signaling pathways. It can bind to the HER2 receptor and block its own phosphorylation process, thereby hindering the conduction of intracellular signaling pathways and inhibiting the proliferation and spread of cancer cells. However, it is worth noting that neratinib may cause some side effects, such as diarrhea, nausea, vomiting, fatigue, etc. Therefore, before using neratinib, doctors will evaluate the patient's overall health and potential risks and develop an individualized treatment plan based on the specific situation.